June 22nd 2020
By Skylar Jeremias
China’s National Medical Products Administration (NMPA) has accepted an application for a biosimilar bevacizumab developed by Bio-Thera Solutions for treatment of certain lung and colorectal cancers.
June 19th 2020
Innovent Biologics said China’s National Medical Products Administration (NMPA) has approved its biosimilar bevacizumab, Byvasda, for use in patients with lung and colorectal cancers.
By Tony Hagen
HLX04, a bevacizumab biosimilar candidate targeted at the colorectal and non–small cell lung cancer markets, met a phase 3 study primary end point, Shanghai Henlius Biotech said.
June 18th 2020
Here is a summary of our coverage from EHA25 Virtual, the annual meeting for the European Hematology Association (EHA).
June 16th 2020
A rituximab biosimilar developed by Celltrion Healthcare demonstrates safety and efficacy in patients with relapsed or refractory aggressive B-cell lymphoma, in findings presented at EHA25 Virtual, the annual meeting of the European Hematology Association.
June 13th 2020
Investigators reported an 88% overall response rate for a Sandoz rituximab biosimilar in combination with chemotherapy in patients with CD20-positive diffuse large B-cell lymphoma.
June 11th 2020
The FDA has approved Pfizer’s pegfilgrastim biosimilar Nyvepria for use in lowering the incidence of infection as manifested by febrile neutropenia.
June 10th 2020
Investigators produced what they described as the first evidence supporting the use of biosimilar erythropoiesis-stimulating agents (ESAs) in patients with myelofibrosis-related anemia.
Canada Health has approved the launch of Sandoz' pegfilgrastim and rituximab biosimilars.
June 9th 2020
By Isha Bangia, PharmD, MBA
Biosimilar discounts to reference products have improved over time, but they are deeper in some categories than others.
